PROF. VALERIE HOX (Orcid ID : 0000-0003-2390-294X)
PROF. MARIANA COUTO (Orcid ID : 0000-0003-4987-9346)
DR. SVEN SEYS (Orcid ID : 0000-0002-4399-9892)
DR. PAVOL SURDA (Orcid ID : 0000-0003-1453-0179)
DR. BRECHT STEELANT (Orcid ID : 0000-0002-0358-9362)

Article type : Review

Tackling nasal symptoms in athletes: moving towards personalized medicine.

Manuscript Acceptance Date: 15-Feb-2021

Short title: Nasal symptoms in athletes

Author list: Hox Valerie[1,2], Beyaert Simon[1], Bullens Dominique[3,4], Couto Mariana[5], Langer Daniel[6], Hellings Peter-Willem[7,4,],Huart Caroline[1], Rombaux Philippe[1], Seys Sven[4], Surda Pavol[8], Walker Abigail[9], Steelant Brecht[4].

Author Affiliations*:*

1. Department of Otorhinolaryngology, CliniquesUniversitaires Saint-Luc, Brussels, Belgium
2. Institute of Experimental and Clinical Research, Pole of Pulmonology, Otorhinolaryngology and Dermatology, UCLouvain, Brussels, Belgium
3. Clinical Division of Pediatrics, University Hospitals, Leuven, Belgium
4. Allergy and Clinical Immunology Research Group, Department of Microbiology, Immunology and Transplantation, KULeuven, Belgium
5. Allergy Unit, Hospital & Instituto CUF Porto, Portugal
6. Respiratory Rehabilitation and Respiratory Division, University Hospitals Leuven, Belgium

7. Clinical Division of Ear, Nose and Throat Disease, Head and Neck Surgery, University Hospitals, Leuven, Belgium
8. Department of Otorhinolaryngology, Guy's and St-Thomas' University Hospital, London, UK
9. Department of Ear, Nose and Throat Disease, St-George Hospital, London, UK

Author contributions:

HV: initiative, conception, drafting, revising, submission of paper
BS: researching for and drafting of paper
BD: conception, drafting, revising of paper
CM: conception, drafting, revising of paper
LD: conception, drafting, revising of paper
HP: conception, drafting, revising of paper
HC: conception, drafting, revising of paper
RP: conception, drafting, revising of paper
SS: conception, drafting, revising of paper
SP: conception, drafting, revising of paper
WA: conception, drafting, revising of paper
SB: conception, drafting, revising of paper

Corresponding author information:
Valerie Hox, Department of Otorhinolaryngology, CliniquesUniversitaires Saint-Luc, Avenue Hippocrate 10, 1200 Brussels, Belgium
Valerie.hox@uclouvain.be

Acknowledgements:VH and CH benefit from a postdoctoral scholarship from the Belgian Fonds National de Recherche Scientique (FNRS). DB and BS benefit from a postdoctoral scholarship from the Belgian FondsvoorWetenschappelijkOnderzoek (FWO).

Conflict of interest statement: A part from the above mentioned nationally funded scholarships, all authors confirm to have no conflict of interest to declare related to the published work.

Abstract

Adequate nasal breathing is indispensable for athletes andnasal symptoms have been shown to interfere with their subjective feeling of comfortable breathing and quality of life. Nasal symptoms are caused by either structural abnormalities or mucosal pathology. Structural pathologies are managed differently from mucosal disease and therefore adequate diagnosis is of utmost importance in athletes in order to choose the correct treatment option for the individual. Literature suggests that nasal symptoms are more prevalent in athletes compared to the general population and certain sport environments might even trigger the development of symptoms. Given the high demands of respiratory function in athletes, insight into triggering factorsis of high importance for disease prevention. Also, it has been suggested that athletes are more neglectful to their symptoms and hence remain undertreated, meaning that special attention should be paid to education of athletes and their caregivers.

This review aims at giving an overview of nasal physiology in exercise as well as the possible types ofnasal pathology. Additionally, diagnostic and treatment options are discussed and we focus on unmet needs for the management and prevention of these symptoms in athletes within the concept of precision medicine.

Keywords: ENT, precision medicine, rhinitis, sinusitis, sports

Word Count:5570

Main Text:

1.Introduction

For elite athletes an optimal health state is indispensable in order to deliver their best athletic performances.Athletes who undertake intense aerobic exercise meet metabolic demands by significantly increasing minute ventilation, making the airways one of their most importantorgan systems. The link between strenuous exercise and asthma has been a long-standing source of research and debate, but more recently, interest in the upper airwaysof athletes has gained more attention. Although it has been demonstrated that the nasal airway contributes onlyfor 10% of minute ventilation at maximal exercise intensity[1], the nose plays an important role in respiratory physiology due to its positionat the entry of the airways. The most important functions of thenasal mucosa is to humidify and heat up the inhaled air, however, it is also the first barrier to encounter and respond to environmental particles such as allergens, pathogens or irritants[2].

Athletes seem to suffer more frequently from nasal symptoms compared to the non-sporting population[3] and some data in literature suggest that factors related to the excessive ventilation and/orenvironmental exposures might be a causal factor for upper airway dysfunction[4, 5].

Up till now,very little data exists on the difficulties that may arise while choosing the adequate treatment strategy for this patient group that presents with specific demands related to their occupation.

The aim of this review is to give an overview on what is currently known on the relevance and causes of the different types of nasal dysfunction in athletes. Additionally,the different treatment options withtheir place within the anti-doping regulations as well as the open questions and unmet needs for the management of this patient group are discussed with an outlook towards further research necessities.

2.Role of sinonasal disease on wellbeing and performances in athletes

Thanks to filtration, humidification and heating of the inhaled air, nasal breathing is more comfortable than oral breathing and human beingsare innate nose breathersat rest. The nasal septum and turbinates that are responsible for these functions,create a high-resistance airway passage inside the nose. During exercise, this resistance leads to an increased breathing effort sensation and when this sensation becomes too uncomfortable, the individual willswitch from nasal to oral breathing[6]. Time points at which this occurs are very variable among subjects, but it is believed to occur when laminar nasal airflow becomes turbulent [7].Oral breathing has been

shown to be more efficient than nasal breathing[8] which also implicates that blocking the nose does not form a limiting factor when looking at objective exercise parameters such as VO_2max[9].

Impact on quality of life (QOL)

Despite this finding that impaired nasal breathing does not directly impair objective physiological outcome, multiple studies have shown a clear impact of nasal symptoms on patients' quality of life (QOL) [10-12]which might indirectly interfere with athletic performances.Katelaris surveyed 214 Olympic athletes and found that those who suffered from a seasonal allergic rhinitis (AR) reported significantly lower QOL scores than non-allergic athletes, which improved as the pollen count declined[13].Walker recently published that QOL related to nasal symptoms,as measured by the Sinonasal outcome test (SNOT) 22 questionnaire, was significantly lower in athletes compared to sedentary controls [3] and lower in athletes suffering from nasal symptoms compared to healthy athletes [14].This questionnaire comprises 22 questions related to sinonasal symptoms as well as related functional and emotional impairment, each scored from 0 to 5 (0 = not impaired; 5 = severely impaired). Surda demonstrated that this effect was greatest in swimmers as measured by the rhinoconjunctivitis quality of life questionnaire (RQLQ) [15]. The RQLQ is a self-administered questionnaire evaluating 7 domains of functional impairment related to rhinoconjunctivitis symptoms that are all scored on a 7-point scale (0 = not impaired, 6 = severely impaired). Thesehigher RQLQ results in swimmers were confirmed by Bougault who evenshowed a normalization of nasal symptoms and QOL after a 2-week resting period [4].

Impact on sleep

Another indirect link between nasal symptoms and athletic performances, is the impact on sleep.Multiple papers have shown the detrimental effect of rhinitis, and especially nasal congestion, on sleep[16].A recent meta-analysis demonstrated that patients with AR scoresignificantly higheron sleep disturbances andsleep latency tests, and that they have lower sleep efficiency scores and report more frequent use of sleep medicationscompared to controls, as measured by the Pittsburgh Sleep Quality Index and polysomnography. They also report more nocturnal dysfunctions, such as insomnia and sleep-related breathing disorders,than individuals without nasal symptoms, as well as more daytime dysfunction including difficulty waking up and daytime dysfunction[17]. Conversely, there is more and more evidence that poor sleep quality can directly impact the performances of athletes [18] with sleep restriction studiesshowing adverse impacts on anaerobic power, isometric force, cortisol level and even shorter running distances on a

30-min treadmill exercise[18, 19]. Also decreased sport-specific performances have been reported after (partial) sleep-deprivation [20, 21].

Impact on athletic performance

Unfortunately, very little studies have evaluated the direct impact ofnasal dysfunction onathletic performances, however there are some papers available that suggest the presence of this link; a recent questionnaire-based study includingmore than 600 marathon runners, demonstrated that over 80% of athletes suffering from AR reported an impact on their performances, based on how often their training activities were disturbed (reduced, postponed or shifted to indoor)during the pollen season[22]. 12.5 % of the runners could not at all exercise because of pollen allergy during the season and another 10 % of participants was affected in more than every second training units/sessions. Another questionnaire-basedstudy questioned recreational athletes suffering from self-reported exercise-induced rhinitis and found that around 45% of these individuals answered "yes"to the question whether their nasal symptoms adversely affected their athletic performances in a moderate or severe way [23].

3. Types and prevalence of nasal dysfunction in athletes

Nasal dysfunction can arise from either mucosal dysfunction or deformity of the anatomicalstructuresMucosal dysfunction can be induced by multiple factors and caneither present as rhinitis which causes symptoms ofnasal obstruction, rhinorrhea, nasal itch and sneezing[24], while rhinosinusitis patients have additional symptoms of facial pain and smell loss [25].

3.1 Infectious rhinitis

Viral rhinitis or 'common cold' is one of the most common diseases worldwide and itwas the principal reason for athletes to consult a doctor during both the Summer and Winter Olympic Games of 2000-2002 [26, 27]. Interestingly, elite athletes suffer more frequently from commons colds compared to recreational athletes[28] and they were more common in athletes with pre-existing nasal symptoms [3]. Data suggests that long-distance running increases thelikelihood of having acommon cold during heavy training or in the period following a marathon [28-32]. These findings implya potential link between acute physical stress and susceptibility to upper respiratory tract infection. An exercise-induced decrease in immunoglobulin (Ig)Asecretion is the most commonly reported explanation, although a study from Peters failed to show this link[32]. Other mechanisms that have been suggested are a decreased NK-cell activity and/or lymphocyte proliferative response after

strenuous exercise[33], but clear evidence is lacking. Also, it should be noted that in 30-40% of studied cases no pathogen could be identified [2], so the infectious component might be overestimated and other causes might lay at the base of the nasal dysfunction.

3.2 Allergic rhinitis

Allergic inflammation is the most common cause of chronic rhinitis and responsible for inducing nasal symptoms after allergen exposure in a sensitized individual through an IgE-induced pathway[34]. A recent systematic review mentions a prevalence of AR in athletes ranging from 21 to 56.5% [35] which is comparable to the prevalence in the general population.When looking at specific sports populations however, aquatic athletes seem to suffer more frequently from AR compared to land-based athletes[36]. This might be explained by the fact that chlorination products might predispose to allergic sensitization[37], however, this could not be confirmed by*in vivo*[38]nor*in vitro*[5] studies. It has been suggested that strenuous exercise may contribute to the development of allergic sensitization after showing a potential shift of the T-lymphocyte population towards a T helper 2 subtype upon excessive exercise[39, 40]. To our knowledge, no study has demonstrated a causal relationship between exercise and allergic sensitization.

3.3 Non-allergic and mixed rhinitis

Non-allergic rhinitis (NAR)is defined as a chronic rhinitis in the absence of infection or systemic allergen-specific IgE and comprises a very heterogenous patient group [41]. In everyday life, an overlap betweenARand NAR is very frequently seen and addressed as mixed rhinitis. So far, reliable data on the occurrence of NAR in the athlete population is scarce but studies reporting on mixed rhinitisshow a prevalence as high as74 % in athletes[35].

Within all sports disciplinesNAR isagain mostfrequently reported in aquatic athletes, possibly due to exposures to pool chlorination products. Several studies showed a significantly higher prevalence of NAR in swimmers compared to non-swimming athletes and controls [3]. Gelardi and colleagues showed that within a population of swimmers with rhinitis, 76% hadNARof whom35% presented with a neutrophilic nasal inflammation[42]. Another study confirmed this neutrophilic nasal influx in swimmers, in combination with an increasedMCTcompared to controls[42, 43].A recent study showed anincreaseof neuropeptides and epithelial injury markers in nasal secretions of swimmers after training, suggesting a direct irritant effect on the airway mucosa of the chlorination products, which has also been shown in a mouse model of chlorine-induced airway hyperreactivity[38].Also, air pollution might induce non-allergic dysfunction: the nasal mucociliary

clearance time (MCT) was prolonged in runners who ran in polluted streets when compared to running in the woods [44], although the inflammatory response to exposure to pollutants seems more mitigated in athletes compared to sedentary controls [45].

3.4 Nasal hyperreactivity

Nasal hyperreactivity (NHR) which is a frequent hallmark of rhinitis, is characterized by the induction of nasal symptoms upon encounter of unspecific environmental stimuli and is believed to play an important role in athletes [46, 47]. Exposure to cold temperatures is one of the most important triggers for NHR [48, 49]The perception of cold temperature is regulated by transient receptor potential melastatin 8 (TRPM8), a cation channel belonging to the TRP superfamily [50, 51]. In the lungs, cold-mediated activation of TRPM8 leads to increased expression of several cytokine and chemokines [51],suggesting a close involvement of TRMP8 in airway inflammatory responses induced by cold air.Li, 2011 #532}.Cold-induced NHR can be an issue for winter-sports athletes; which has been confirmed by Bonadonna who reported on a prevalence of almost 50 % of cold-induced rhinorrhea in over a hundred skiers, independent from their atopy state[52].Also exposures to environmental irritants such as pollution and chlorination products in outdoor and aquatic athletes, might induce rhinitis symptomsin those with pre-existing rhinitis with NHR, even in the absence of a direct irritant effect. This reaction is most likely also provoked via activation of the sensory nerves expressing TRP-receptors since TRPA1 has been emerged as the major airway irritant detector[53].

3.5Exercise-induced rhinitis

It has been postulated that laborious exercise has a direct negative effect on nasal functioning and can lead to "exercise-induced rhinitis". In healthy individuals, exercise promotes a decrease in nasal airway resistance due to an increased sympathetic tone upon a rise in the arterial pCO2 [54], however, in patients suffering from pre-existing rhinitis, isometric exercise induces conversely an increase in nasal resistance, probably due to an abnormal neurogenic regulation of the nasal mucosa in these patients [48]. There is also data that strenuous exercise can lead to rhinitis symptoms and nasal inflammatory changes by itself. One study found a nasal neutrophil influx after a 20 km race in combination with a significantly prolongedMCT after the race [55].At the level of the lower airways, two distinct exercise-induced phenotypes are described; exercise-induced asthma (EIA) and exercise-induced bronchoconstriction (EIB). EIA implies a background of airway hyperresponsiveness that may be exacerbated by exercise. EIB implies airway

hyperresponsiveness that is solely triggered by exercise. It can be accepted that the same holds true for rhinitis and a distinction between exercise-induced rhinitis (EIR) and exercise-induced nasal hyperreactivity (EINHR)can be a topic for future discussion.

3.6 Rhinosinusitis

To our knowledge, hardly anything is known about rhinosinusitis in athletes.Gelardimentions in his study that 3% of swimmers had an acute rhinosinusitis[42] and one other study describes sinonasal mucosal hypertrophyin divers, possibly due to pressure differences[56].However, to our knowledge, no study has investigated the presence of chronic rhinosinusitis (CRS) in the athletic population, although an increased prevalence lies within the line of expectation since infection and atopy are considered to be risk factorsfor CRS[25].

3.7 Structural pathology

Not all nasal symptoms are due to mucosal pathology and structural abnormality of the nasal septum, pyramid or tip, is one of the most common reasons for nasal obstruction [57]and might be congenital or acquired. In these patients, nasal airway resistance is increased, which can lead to reducedoruncomfortable nasal breathing[58].The impact of this nasal obstruction on QOL is measured by the nasal obstruction evaluation (NOSE) questionnaire that consists of 5 questions scored from 0 (no problem) to 4 (severe problem) and even includes the question about the individual's ability to get enough air through his/her nose during exercise, highlighting the importance of a patent nasal airway during sports. In certain contact sports, nasal trauma is a frequent complication that can potentially lead tostructural pathology. This was confirmed byPassaliwho demonstrated in seventeen boxers a significantly higher nasal resistance, compared to the normal population reference values[59].Other studies that support the importance of structural pathology in exercise are the studies that discuss the effect of nasal dilators that decrease the nasal resistance and are discussed below.

4. Mechanisms of upper airway illnesses in athletes

Although more and more attention has gone towards the mechanisms of asthma symptoms in athletes, studies focusing on upper airway pathophysiology in this population are rather scarce. However, the upper airway epithelium is the gateway keeper of the respiratory tract and continuously exposed to environmental molecules and physical strains.It consists of several cell

types, each playing their role in modulating mucosal homeostasis[60]. Several mechanisms that interfere with this homeostasis may be involved in the development of upper airway symptoms in athletes [29, 61] (Figure 1). When looking at the lower airways, the classical theory explaining EIB states that the increased ventilation during intense exercise induces water loss, cooling and dehydration of the airway mucosa which lead to a secondary stimulation of the cholinergic receptors. But there is more and more evidence that increased ventilation and sports-specific environmental factors (e.g. pollution, cold air or chlorination products)can cause a direct epithelial damage, inducing airway inflammation [62]. Additionally, also the sensory nerves can detect and respond to both cold temperatures [63] and humidity [64] via the TRP receptors. With regards to the concept of the global airway, one can speculate that similar mechanisms are playing at the level of the upper airways. The potential interplay between these exogenous and endogenous factors is depicted in Figure 1.

5. Diagnosis

Diagnosis starts with taking a thorough historyabout symptoms, sportenvironment and a possible link between these two. Questions about triggering factorsor symptom improvement after a resting break or treatment are useful.Clinical examination should include both evaluation of the external and internal nose.The general aspect of the nasal mucosa, the nasal septum and the nasal valve can be appreciatedwith anterior rhinoscopy. Nasal endoscopy offers the advantage of a global evaluation of the nasal cavity and sinus outflow tracts [65]. Examination of the external nasal pyramid and tip with valve tests will give information about important structural abnormalities, nasal valve dysfunction and alar collapse.[66].

Technical exams such asanterior rhinomanometry, acoustic rhinometry and peak nasal inspiratory flow (PNIF) measurements and can be used to objectify reported nasal blockage and measure nasal resistance[67]. However, these objective measurements do not always correspond well with symptoms of nasal obstruction and results should always be correlatedwith subjective parameters.

Every athlete with airway symptoms should be screened for allergies asa causal factor of rhinitis.The validated AQUA questionnaire is often used to identifyathletes with allergic disease[68].Although a useful screening tool (specificity of 97.1% when score > 5), the sensivity is quite low (58.3%)[69]and might be due to the fact that athletes often misinterpret the cause of their nasal symptoms as being allergic or not. Since several of the epidemiological studies in athletes

are based on this questionnaire [70, 71], the current prevalence of AR among athletes remains unclear. However, the finaldiagnosis of AR is based upon a correlation between typical nasal symptoms and the systemic detection of allergen-specific IgE, either by skin prick test (SPT) or in the serum[72]. One Polish study that combined data from the AQUA questionnaire with SPT and previous doctor diagnosisin 220 Olympians, found a clear mismatch between self-reported AR (27%), SPT-confirmed AR (21%) and doctor-diagnosed AR (9%)[73].

When allergic symptoms and systemic IgE detection do not correlate, a specific nasal allergen challenge (NAC)can be considered[74]. Nasal cold dry air (CDA) challenge can objectify the presence of NHR [49].Unlike exercise-induced bronchoconstriction (EIB), no specific test iscurrently available to diagnose exercise-induced rhinitis which is consequentlysolely based on history and self-reporting.

6. Treatment options

Different types of nasal pathology in athletes should be treated according to the respective guidelines [24, 25, 75]. However,due to the World Anti-Doping Agency (WADA) regulations [76], athletes ought to adhere to strict regulations in terms of pharmacological treatment. Treatment differs between mucosal and structural pathology and options are summarized in table 1.

6.1 Treatment of mucosal pathology

6.1.1 Trigger avoidance

A very safe, cheap and adequate treatment option is the avoidance of triggering agents[77]. For AR patients, this means allergen avoidance, but for all athletes suffering from NHR, exposure to unspecific triggers such as airway irritants, pollution and cold temperatures should be circumvented whenever possible. For some athletes this may be hard to accomplish; winter sport athletes cannot avoid exposure to cold temperatures and outdoor athletes will always be exposed to pollens and/or pollution. Also,for swimmers,exposure to chlorination products is basically unavoidable. In indoor pools, trichloramine is the chlorination byproduct that is most closely related with respiratorysymptoms[78, 79]and the WHO regulations demand a maximum level of 0.5mg/m^3 trichloramine in the air of indoor swimming pools [80]. Yet, in most countries regular monitoring of swimming pool water and air is rarely performed.

6.1.2. Saline douches:

Nasal douching is cheap and safe, and an important part of the management of both rhinitis and rhinosinusitis that do not interfere with the WADA regulations. Especially insymptomatic athletes exposed to irritants (swimmers, runners in polluted areas) this is a valuable option. Since the WHO recommends to shower and clean off the chlorine after exposure to a chlorinated swimming pool[80], it seems logical to clean the nasal mucosa after swimming, although no data are available on the action of nasal salinedouchings in rhinitis prevention.

6.1.3. Decongestants

Short-course treatment with nasal or oral decongestant can be beneficial in treating a common cold but should be limited to a maximum of 7 days. WADA allowssome decongestants (caffeine, phenylephrine, phenylpropanolamine,adrenaline, xylometazoline and synephrine) and restricts others to a certain dose ((methyl)ephedrine < 10 μg /ml and Pseudoephedrine < 150 μg /ml in urine). Most other decongestants, especially those containing sympathomimetic amines or stimulants are currently prohibited by the WADA[76]; The list of prohibited drugs changes annually, so physicians should verify when prescribingthese products to athletes.Moreover, the use of oral decongestants can lead to a series of side effects such as tachycardia, tremor, insomnia, elevated heart rate and blood pressure, which can be problematic for athletes. Unfortunately, in many countries these drugs are available on an over-the-counter base and therefore athletes need to be counseled about the actual prohibited substances.

Decongestants do not have a part in the treatment ofAR, NAR or CRS because of the risk of inducing rhinitis medicamentosa, a decongestant-induced paradoxical swelling of the nasal mucosa.

6.1.4. Glucocorticosteroids

Intranasal steroids (INS) as a maintenance treatment are the first therapy of choice in moderate/severe and persistent AR, CRS and most forms of NAR[24, 25, 75].In athletes specifically, they have shown to reduce symptoms and improve QOL significantly for AR [81]. Furthermore, they are known to have a beneficial effect on asthma symptoms [24].Interestingly, the use of INS has been reported to revert the paradoxical increase in nasal resistance upon isometric exercise which is seen in NAR [48] and might therefore be the ideal treatment for athletes with NAR and/or exercise-induced rhinitis.

The use of INS is presently permitted by WADA without a therapeutic use exemption (TUE)[76]. However, literature suggests that athletes may not be fully aware of those regulations since several

studies show that athletes with rhinitis are much less adherent to their INS compared to non-athletes;Surda showed that chronic nasal medication was significantly less taken by elite swimmers with nasal symptoms (18%) compared to symptomatic non-sporting controls (67%) [3] and Walker showed that elite hockey players were much less adherent to their INS compared to non-elite players and sedentary controls [14].Adverse effects ofINSinclude minor epistaxis, crusting, nasal dryness and irritation of the throat and nose, however,most of these side-effects are transient and rarely require stoppingINS treatment, even on a long-term base.

It is worthwhile mentioning that WADA allows physicians to treat severe ARwith systemic glucocorticosteroids under the TUE rule.However, in view of the possible side effects, indications for treating AR with oral or depot steroids are extremely rare and preserved for uncontrolled AR with severe symptoms not responding to any other medical therapy including allergen immunotherapy[82].

6.1.5. Antihistamines

Antihistaminesare a first-line treatment for athletes suffering from AR and are currently allowed by the WADA regulations[76]. They are very effective for treating histamine-induced symptoms such as rhinorrhea, sneezing and itch, but are somewhat less effective on nasal obstruction[83]and therefore often combined with INS.Surprisingly, two RCTs have also shown a beneficial effect of topical azelastine in NAR patients[84, 85], probably due to secondary effects on neuropeptide release.In most countries, a combination formulation of intranasal azelastine with the INS fluticasone proprionate (MP-029) is available and has been shown to be effective in reducing symptoms in a population of both AR and NAR patients [86]with a specific reduction of NHR in AR patients [87].

The above-mentioned studyby Walker however, has shown that antihistamineswere rarely used by elite hockey players when compared to recreational players or non-sporting controls [14]. It was believed to be due to the athletes'fear of side effects of these kind of drugs or misperception of WADA regulations. Nonetheless, it is well-known that second-generation antihistamines are much less sedative than older antihistamines and cardialarythmiasare only seen with overdosing[88, 89]. Topical antihistamines haveno side effects but the disadvantage of shorter duration of activity [24].

6.1.6. Cromoglycates

Cromolyns are mast cell stabilizers that can be used intranasally. They are moderately effective in treating mast-cell related nasal symptoms (itch, rhinorrhea, sneezing)[24] but inferior to

antihistamines. Despite their short half-life and duration of activity, they show a very good safety profileand are at the moment authorized by the WADA's regulation[76].

6.1.7. Antileukotrienes

Leukotriene receptor antagonists block the functions of leukotrienes on the local environment and have been shown tohave anefficacyin ARpatients comparable to antihistamines[24] and might be an added value in athletes suffering from AR with concomitant asthma [90].In contrast to antihistamines, they do not cause sedation and they are currently also permitted by the WADA regulation[76].

6.1.8. Allergen Immunotherapy

Allergen immunotherapy (AIT)is the only disease-modifying treatment option for athletes suffering from AR, because of its capability to induce immune tolerance leading to long termdisease control [91].Multiple studies have proven that AIT is effective in reducing symptoms andrescue medication, as well as in improving QOL in the general AR population[91]. AIT isadministered either subcutaneously (SCIT) or in a sublingual way (SLIT) with SCIT being slightly more effective but SLIT showing a better safety profile. Both types are permitted by the WADA regulations[76]. SCIT usually precludes performing exercise on the administration day, which should be a factor to be consideredin athletes.

To our knowledge, there is only one study that included athletes on AIT; this German questionnaire-based study comparedathletes with AR treated by AIT to athletes with AR, treated by either pharmacological or non-pharmacological alternative treatments[22]. Although appropriate statistical calculations are missing, they show that in athletes treated by AIT, the pollen season had a lower effect on their trainings, compared to AR athletes treated by other means. These results might be biased by the fact that AIT patients per definition have sought medical help and are in medical follow-up, while this is not necessarily the case for the other groups.Interestingly, a post-hoc analysis showed that the majority of athletes were not aware or had misbeliefs about the different anti-allergic treatment options, which is not very different from the general population.Practically, when prescribed in athletes, it is recommended to start AIT a few months before the competitive season because the initial phase can be accompanied with local or systemic side effects, more so for SCIT than fore SLIT.

6.2. Treatment of structural pathology

6.2.1. Nasal dilators

Nasal dilators can be either fixed on the nasal dorsum or introduced in the nostrils, in order to open up the nasal valve region and reduce airflow resistance at this highly resistant area.These dilators are an elegant, non-surgical solution for alar insufficiency, leading to an important increase of nasal flow and good patient satisfaction in the general population[92]. They became very popular in the late eighties in the athletic population because they were initially believed to improve performances.Dinardi recently reviewed the effects of external nasal dilators on physical exercise [93] and performed one study using an internal nasal dilator[94].Most of the studies reviewed are of limited methodological quality and fail to demonstrate an objective effect on total VO_2max, heart rate or total exercise time [93], but some studies indicate that nasal dilators can improve subjective exertion rates [95] and nasal breathing [96] during exercise. This corresponds to what is found in the non-athletic population where nasal dilators can also improve subjective nasal breathing in patients with nasal valve dysfunction. It needs to be noted that almost allof the exercise-based studies were performed in asymptomatic healthy athletes;only one has considered nasal dilators in adolescents with AR [97]. However, none of these studies reported on rhinoscopy findingsor data on structural abnormalities such as septal deviation or valve pathology in the tested athletes, which would be the key determinants for the therapeutic effect of nasal dilators.

6.2.2. Surgery

Nasal surgery can bea treatment option for medically resistant nasal obstruction due to structural pathology at the level of the nasal bones or cartilage.

Septoplasty is the most commonly performed surgical ENT intervention in adults; however, due to a lack of controlled trials, clear evidence on its effectiveness is currently lacking[98].One of the possible reasons for septoplasty failure could be an unaddressed nasal valve insufficiency. In this case, septorhinoplastycould bring a solution, although also for this type of intervention, evidence on functional benefit is mostly lacking.Endoscopic sinus surgery is indicated in CRS patients who fail to respond to maximal medical therapy[25].

To our knowledge, apart from one study showing a benefit of early reduction of sports-induced nasal fracture [99], no studies are available on the benefit of nasal surgery in athletes.As is the case for the general population, the key factor is to make the correct surgical indication and mucosal pathology should be excluded and/or treated before deciding on surgical intervention.

7.Recommendations for the application of personalized medicine

It goes without saying that not every therapeutic option mentioned in the previous paragraph, is suitable for every athlete that suffers from nasal symptoms. In order to offer an optimized treatment to every symptomatic athlete, we suggest to follow the concept of precision-based medicine, which is based on the 4P's: prediction, prevention, personalization and participation[100](Figure 2). By predicting which athletes are at risk to develop nasal symptoms and which of them will be most bothered by them, early interference might prevent the development of symptoms or their interference with athletic performances. Reducing exposures to sensitized allergens and irritants where-ever possible, can prevent the development or aggravation of nasal symptoms. By investing in an adequate diagnosis of the cause and type of nasal symptoms, a more personalized therapeutic strategy can be offered to the symptomatic athlete. A diagnostic algorithm including history, clinical examination, endoscopy, imaging and technical exams, can help the physician to obtain an adequate diagnosis (Figure 3).Following this diagnostic algorithm, there can be decided upon more or less advanced therapeutic interventions according to the impact of the symptoms on QOL and/or performances. For most of the athletes that suffer from rhinitis or rhinosinusitis, pharmacological treatment will be part of their management scheme.However, therapeutic adherence is an important issue in athletes[22] and participation of both patient and health care provider forms an essential part of their treatment. They should be informed about their disease and its impact, efficacy of pharmacological and non-pharmacological treatments, possible side-effects and how they fit within the WADA-regulations. Since WADA-regulations change constantly, updated and country-specific information on the prohibited status of medication can be sought via the website of Global Drug Reference Online (Globaldro) [101]. Disease-specific smartphone applications delivering patient education and following symptoms might be useful within this regard.A list of strategies that can be appliedfor the implementation of the 4 P'sisgiven in Table 2.

8.Unmet scientific needs and future perspectives

Due to a lack of knowledge, evidence and attention for the impact of nasal symptoms on athletic performances in athletes, several unmet needs persist regarding this topic[105, 106]. First of all, more well-designed epidemiological studies are needed, involving both experts in sports medicine as well as in upper airway pathology, in order to get a proper idea about the occurrence of the

different types of rhinitis and rhinosinusitis, using proper definitions and diagnosis by specialists. This could not only give us an indication about the true frequency of this problem, but also about the (sports-related) risk factors for both allergic as well as non-allergic subtypes. Ideally, these studies need to include questions and outcome parameters of athletic performances in order to determinea possible direct impact of upper airway symptoms on the athlete's performance.

In the last decades, a lot of research has been devoted to investigate mechanisms, diagnosis and management of EIB. Unfortunately, this does not hold true for its upper airway counterpart and at present, we are not sure whether EIR is a true concept and how it should be defined.Adequately set-up studies investigating athletes from variable sport-categories and variable sport-specific environments, should examine functional and immunological changes in the nasal airway before and after exercise.Gaining more insight in mechanisms of upper airway symptoms in athletes related to exercise and unfavourable circumstances will lead to a better clinical diagnosis and individual-tailored treatment in athletes.

Within this regard, various non-pharmacological interventions, such as pre-exercise nasal saline rinses or warm-up exercises, that might interfere with sports-related strains on the upper airway mucosa, need to be investigated.

Currently, basically nothing is known about the impact of nasal structural abnormalities leading toa narrow nasal valve areaon nasal breathing during exercise, despite the fact that increased nasal flow generally worsens the valve problem.None of the studies that investigate the effects of nasal dilators in athletes have looked at the presence of septal deviations or nasal valve dysfunction, while this is a key aspect to consider when prescribing devices that open up the nasal valve. Since elective surgery is often not easy to fit into a busy training scheme, nasal dilators might be a good (temporary) option in athletes that suffer from nasal valve dysfunction.A proposal for future studies that can be designed in order to answer the above-mentioned questions and needs is made in Table 3.

9.Conclusion

Regarding the obvious importance of adequate breathing for athletes, a lot of attention has been paid to lower airway symptoms in this population. Because of the minor effects of improving nasal patency on objective physiological exercise parameters, nasal symptoms are often overlooked in athletes However, in addition to the well-known impact of nasal symptoms on QOL

in general, subjective exercise parameters such as exertion perception and breathing comfort are affected by nasal dysfunction. Therefore,we plead for an increased awareness for nasal symptoms in the athletic population in order to improve early diagnosis and provide precision-based treatment options to athletes suffering from nasal dysfunction.

References

1. Katz RM. Rhinitis in the athlete. J Allergy Clin Immunol. 1984;73(5 Pt 2):708-11.
2. Spence L, Brown WJ, Pyne DB, Nissen MD, Sloots TP, McCormack JG, et al. Incidence, etiology, and symptomatology of upper respiratory illness in elite athletes. Medicine and science in sports and exercise. 2007;39(4):577-86.
3. Walker AC, Surda P, Rossiter M, Little SA. Nasal disease and quality of life in athletes. J Laryngol Otol. 2018;132(9):812-5.
4. Bougault V, Turmel J, Boulet LP. Effect of intense swimming training on rhinitis in high-level competitive swimmers. ClinExpAllergy. 2010;40(8):1238-46.
5. Steelant B, Hox V, Van Gerven L, Dilissen E, Dekimpe E, Kasran A, et al. Nasal symptoms, epithelial injury and neurogenic inflammation in elite swimmers. Rhinology. 2018;56(3):279-87.
6. Classifying recommendations for clinical practice guidelines. Pediatrics. 2004;114(3):874-7.
7. Wang de Y, Lee HP, Gordon BR. Impacts of fluid dynamics simulation in study of nasal airflow physiology and pathophysiology in realistic human three-dimensional nose models. Clinical and experimental otorhinolaryngology. 2012;5(4):181-7.
8. Recinto C, Efthemeou T, Boffelli PT, Navalta JW. Effects of Nasal or Oral Breathing on Anaerobic Power Output and Metabolic Responses. International journal of exercise science. 2017;10(4):506-14.
9. Meir R, Zhao GG, Zhou S, Beavers R, Davie A. The acute effect of mouth only breathing on time to completion, heart rate, rate of perceived exertion, blood lactate, and ventilatory measures during a high-intensity shuttle run sequence. Journal of strength and conditioning research. 2014;28(4):950-7.
10. Campbell AP, Hoehle LP, Phillips KM, Caradonna DS, Gray ST, Sedaghat AR. Depressed mood is associated with loss of productivity in allergic rhinitis. Allergy. 2018;73(5):1141-4.
11. Canonica GW, Mullol J, Pradalier A, Didier A. Patient perceptions of allergic rhinitis and quality of life: findings from a survey conducted in europe and the United States. The World Allergy Organization journal. 2008;1(9):138-44.
12. Khan A, Huynh TMT, Vandeplas G, Joish VN, Mannent LP, Tomassen P, et al. The GALEN rhinosinusitis cohort: chronic rhinosinusitis with nasal polyps affects health-related quality of life. Rhinology. 2019;57(5):343-51.
13. Katelaris CH, Carrozzi FM, Burke TV, Byth K. A springtime olympics demands special consideration for allergic athletes. J Allergy Clin Immunol. 2000;106(2):260-6.

14. Walker A, Surda P, Rossiter M, Little S. Rhinitis in Elite and Non-Elite Field Hockey Players. International journal of sports medicine. 2017;38(1):65-70.
15. Surda P, Putala M, Siarnik P, Walker A, Bernic A, Fokkens W. Rhinitis and its impact on quality of life in swimmers. Allergy. 2018;73(5):1022-31.
16. Lunn M, Craig T. Rhinitis and sleep. Sleep Med Rev. 2011;15(5):293-9.
17. Liu J, Zhang X, Zhao Y, Wang Y. The association between allergic rhinitis and sleep: A systematic review and meta-analysis of observational studies. PLoS One. 2020;15(2):e0228533.
18. Charest J, Grandner MA. Sleep and Athletic Performance: Impacts on Physical Performance, Mental Performance, Injury Risk and Recovery, and Mental Health. Sleep Med Clin. 2020;15(1):41-57.
19. Oliver SJ, Costa RJ, Laing SJ, Bilzon JL, Walsh NP. One night of sleep deprivation decreases treadmill endurance performance. Eur J Appl Physiol. 2009;107(2):155-61.
20. Reyner LA, Horne JA. Sleep restriction and serving accuracy in performance tennis players, and effects of caffeine. Physiol Behav. 2013;120:93-6.
21. Souissi N, Chtourou H, Aloui A, Hammouda O, Dogui M, Chaouachi A, et al. Effects of time-of-day and partial sleep deprivation on short-term maximal performances of judo competitors. Journal of strength and conditioning research. 2013;27(9):2473-80.
22. Salem L, Dao VA, Shah-Hosseini K, de Marees M, Mester J, Mosges R, et al. Impaired sports performance of athletes suffering from pollen-induced allergic rhinitis: a cross-sectional, observational survey in German athletes. The Journal of sports medicine and physical fitness. 2019;59(4):686-92.
23. Silvers WS, Poole JA. Exercise-induced rhinitis: a common disorder that adversely affects allergic and nonallergic athletes. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology. 2006;96(2):334-40.
24. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63 Suppl 86:8-160.
25. Fokkens WJ, Lund VJ, Mullol J, Bachert C, Alobid I, Baroody F, et al. EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology. 2012;50(1):1-12.
26. Reeser JC, Willick S, Elstad M. Medical services provided at the Olympic Village polyclinic during the 2002 Salt Lake City Winter Games. WMJ : official publication of the State Medical Society of Wisconsin. 2003;102(4):20-5.
27. Robinson SR, Wormald PJ. Endoscopic vidian neurectomy. American journal of rhinology. 2006;20(2):197-202.

28. Nieman DC, Johanssen LM, Lee JW, Arabatzis K. Infectious episodes in runners before and after the Los Angeles Marathon. The Journal of sports medicine and physical fitness. 1990;30(3):316-28.
29. Gleeson M, Pyne DB, Austin JP, Lynn Francis J, Clancy RL, McDonald WA, et al. Epstein-Barr virus reactivation and upper-respiratory illness in elite swimmers. Medicine and science in sports and exercise. 2002;34(3):411-7.
30. Makela MJ, Puhakka T, Ruuskanen O, Leinonen M, Saikku P, Kimpimaki M, et al. Viruses and bacteria in the etiology of the common cold. J Clin Microbiol. 1998;36(2):539-42.
31. Peters EM, Bateman ED. Ultramarathon running and upper respiratory tract infections. An epidemiological survey. S Afr Med J. 1983;64(15):582-4.
32. Peters EM, Shaik J, Kleinveldt N. Upper respiratory tract infection symptoms in ultramarathon runners not related to immunoglobulin status. Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine. 2010;20(1):39-46.
33. Walsh NP, Gleeson M, Shephard RJ, Gleeson M, Woods JA, Bishop NC, et al. Position statement. Part one: Immune function and exercise. Exercise immunology review. 2011;17:6-63.
34. Greiner AN, Hellings PW, Rotiroti G, Scadding GK. Allergic rhinitis. Lancet. 2011;378(9809):2112-22.
35. Surda P, Walker A, Limpens J, Fokkens W, Putala M. Nasal changes associated with exercise in athletes: systematic review. J Laryngol Otol. 2018;132(3):191-7.
36. Surda P, Walker A, Putala M, Siarnik P. Prevalence of Rhinitis in Athletes: Systematic Review. Int J Otolaryngol. 2017;2017:8098426.
37. Bernard A, Nickmilder M, Voisin C, Sardella A. Impact of chlorinated swimming pool attendance on the respiratory health of adolescents. Pediatrics. 2009;124(4):1110-8.
38. Hox V, Vanoirbeek JA, Alpizar YA, Voedisch S, Callebaut I, Bobic S, et al. Crucial role of transient receptor potential ankyrin 1 and mast cells in induction of nonallergic airway hyperreactivity in mice. Am J Respir Crit Care Med. 2013;187(5):486-93.
39. Lakier Smith L. Overtraining, excessive exercise, and altered immunity: is this a T helper-1 versus T helper-2 lymphocyte response? Sports Med. 2003;33(5):347-64.
40. Steensberg A, Toft AD, Bruunsgaard H, Sandmand M, Halkjaer-Kristensen J, Pedersen BK. Strenuous exercise decreases the percentage of type 1 T cells in the circulation. J Appl Physiol (1985). 2001;91(4):1708-12.
41. Bachert C, Van Cauwenberghe P, Olbrecht J, Van Schoor J. Prevalence, Classification and Perception of Allergic and Non-allergic Rhinitis. Allergy. 2006;61(6):693-8.

42. Gelardi M, Ventura MT, Fiorella R, Fiorella ML, Russo C, Candreva T, et al. Allergic and non-allergic rhinitis in swimmers: clinical and cytological aspects. Br J Sports Med. 2012;46(1):54-8.
43. Ottaviano G, Staffieri A, Stritoni P, Ermolao A, Coles S, Zaccaria M, et al. Nasal dysfunction induced by chlorinate water in competitive swimmers. Rhinology. 2012;50(3):294-8.
44. Cavalcante de Sa M, Nakagawa NK, Saldiva de Andre CD, Carvalho-Oliveira R, de Santana Carvalho T, Nicola ML, et al. Aerobic exercise in polluted urban environments: effects on airway defense mechanisms in young healthy amateur runners. Journal of breath research. 2016;10(4):046018.
45. Santos J, Foster R, Jonckheere AC, Rossi M, Luna Junior LA, Katekaru CM, et al. Outdoor Endurance Training with Air Pollutant Exposure Versus Sedentary Lifestyle: A Comparison of Airway Immune Responses. International journal of environmental research and public health. 2019;16(22).
46. Doulaptsi M, Steelant B, Prokopakis E, Ierodiakonou D, Tsinaslanidou Z, Cools L, et al. Prevalence and impact of nasal hyperreactivity in chronic rhinosinusitis. Allergy. 2020.
47. Van Gerven L, Steelant B, Hellings PW. Nasal hyperreactivity in rhinitis: A diagnostic and therapeutic challenge. Allergy. 2018.
48. Jones AS. Autonomic reflexes and non-allergic rhinitis. Allergy. 1997;52(36 Suppl):14-9.
49. Van Gerven L, Boeckxstaens G, Jorissen M, Fokkens W, Hellings PW. Short-time cold dry air exposure: a useful diagnostic tool for nasal hyperresponsiveness. Laryngoscope. 2012;122(12):2615-20.
50. Bautista DM, Siemens J, Glazer JM, Tsuruda PR, Basbaum AI, Stucky CL, et al. The menthol receptor TRPM8 is the principal detector of environmental cold. Nature. 2007;448(7150):204-8.
51. Sabnis AS, Shadid M, Yost GS, Reilly CA. Human lung epithelial cells express a functional cold-sensing TRPM8 variant. Am J Respir Cell Mol Biol. 2008;39(4):466-74.
52. Bonadonna P, Senna G, Zanon P, Cocco G, Dorizzi R, Gani F, et al. Cold-induced rhinitis in skiers--clinical aspects and treatment with ipratropium bromide nasal spray: a randomized controlled trial. American journal of rhinology. 2001;15(5):297-301.
53. Bautista DM, Jordt SE, Nikai T, Tsuruda PR, Read AJ, Poblete J, et al. TRPA1 mediates the inflammatory actions of environmental irritants and proalgesic agents. Cell. 2006;124(6):1269-82.
54. Baraniuk JN, Merck SJ. Nasal reflexes: implications for exercise, breathing, and sex. Current allergy and asthma reports. 2008;8(2):147-53.

55. Muns G, Rubinstein I, Singer P. Neutrophil chemotactic activity is increased in nasal secretions of long-distance runners. International journal of sports medicine. 1996;17(1):56-9.
56. Sonmez G, Uzun G, Mutluoglu M, Toklu AS, Mutlu H, Ay H, et al. Paranasal sinus mucosal hypertrophy in experienced divers. Aviation, space, and environmental medicine. 2011;82(10):992-4.
57. Fischer H, Gubisch W. Nasal valves--importance and surgical procedures. Facial plastic surgery : FPS. 2006;22(4):266-80.
58. Chen XB, Lee HP, Chong VF, Wang de Y. Impact of inferior turbinate hypertrophy on the aerodynamic pattern and physiological functions of the turbulent airflow - a CFD simulation model. Rhinology. 2010;48(2):163-8.
59. Passàli D, Damiani V, Passàli GC, Passàli FM, Bellussi L. Alterations in rhinosinusal homeostasis in a sportive population: our experience with 106 athletes. European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery. 2004;261(9):502-6.
60. Hellings PW, Steelant B. Epithelial barriers in allergy and asthma. J Allergy Clin Immunol. 2020;145(6):1499-509.
61. Colbey C, Cox AJ, Pyne DB, Zhang P, Cripps AW, West NP. Upper Respiratory Symptoms, Gut Health and Mucosal Immunity in Athletes. Sports Med. 2018;48(Suppl 1):65-77.
62. Couto M, Kurowski M, Moreira A, Bullens DMA, Carlsen KH, Delgado L, et al. Mechanisms of exercise-induced bronchoconstriction in athletes: Current perspectives and future challenges. Allergy. 2018;73(1):8-16.
63. Li M, Li Q, Yang G, Kolosov VP, Perelman JM, Zhou XD. Cold temperature induces mucin hypersecretion from normal human bronchial epithelial cells in vitro through a transient receptor potential melastatin 8 (TRPM8)-mediated mechanism. J Allergy Clin Immunol. 2011;128(3):626-34 e1-5.
64. Liu L, Li Y, Wang R, Yin C, Dong Q, Hing H, et al. Drosophila hygrosensation requires the TRP channels water witch and nanchung. Nature. 2007;450(7167):294-8.
65. Hellings PW, Scadding G, Alobid I, Bachert C, Fokkens WJ, Gerth van Wijk R, et al. Executive summary of European Task Force document on diagnostic tools in rhinology. Rhinology. 2012;50(4):339-52.
66. Hamilton GS, 3rd. The External Nasal Valve. Facial plastic surgery clinics of North America. 2017;25(2):179-94.

67. Ottaviano G, Fokkens WJ. Measurements of nasal airflow and patency: a critical review with emphasis on the use of peak nasal inspiratory flow in daily practice. Allergy. 2016;71(2):162-74.
68. Jonckheere AC, Seys SF, Dilissen E, Marijsse G, Schelpe AS, Van der Eycken S, et al. AQUA((c)) Questionnaire as prediction tool for atopy in young elite athletes. Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology. 2018;29(6):648-50.
69. Bonini M, Braido F, Baiardini I, Del Giacco S, Gramiccioni C, Manara M, et al. AQUA: Allergy Questionnaire for Athletes. Development and validation. Medicine and science in sports and exercise. 2009;41(5):1034-41.
70. Bonini M, Gramiccioni C, Fioretti D, Ruckert B, Rinaldi M, Akdis C, et al. Asthma, allergy and the Olympics: a 12-year survey in elite athletes. Curr Opin Allergy Clin Immunol. 2015;15(2):184-92.
71. Thomas S, Wolfarth B, Wittmer C, Nowak D, Radon K, study-Team GAL-O. Self-reported asthma and allergies in top athletes compared to the general population - results of the German part of the GA2LEN-Olympic study 2008. Allergy Asthma Clin Immunol. 2010;6(1):31.
72. Brozek JL, Bousquet J, Baena-Cagnani CE, Bonini S, Canonica GW, Casale TB, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol. 2010;126(3):466-76.
73. Kurowski M, Jurczyk J, Krysztofiak H, Kowalski ML. Exercise-induced respiratory symptoms and allergy in elite athletes: Allergy and Asthma in Polish Olympic Athletes (A(2)POLO) project within GA(2)LEN initiative. Clin Respir J. 2016;10(2):231-8.
74. Auge J, Vent J, Agache I, Airaksinen L, Campo Mozo P, Chaker A, et al. EAACI Position paper on the standardization of nasal allergen challenges. Allergy. 2018;73(8):1597-608.
75. Hellings PW, Klimek L, Cingi C, Agache I, Akdis C, Bachert C, et al. Non-allergic rhinitis: Position paper of the European Academy of Allergy and Clinical Immunology. Allergy. 2017;72(11):1657-65.
76. World anti-doping code, (2020).
77. Santos A CM, Delgado L. Best buys for allergic rhinitis and chronic rhinosinusitis prevention and control. In: Akdis CA HP, Agache I, editor. Global atlas of allergic rhinitis and chronic rhinosinusitis: European Academy of Allergy and Clinical Immunology; 2015.
78. Fantuzzi G, Righi E, Predieri G, Giacobazzi P, Petra B, Aggazzotti G. Airborne trichloramine (NCl(3)) levels and self-reported health symptoms in indoor swimming pool workers: dose-response relationships. Journal of exposure science & environmental epidemiology. 2013;23(1):88-93.

79. Seys SF, Feyen L, Keirsbilck S, Adams E, Dupont LJ, Nemery B. An outbreak of swimming-pool related respiratory symptoms: An elusive source of trichloramine in a municipal indoor swimming pool. International journal of hygiene and environmental health. 2015;218(4):386-91.
80. WHO. Guidelines for safe recreational water environments. Volume 2, Swimming pools and similar environments. In: Organization WH, editor. 2006.
81. Katelaris CH, Carrozzi FM, Burke TV, Byth K. Effects of intranasal budesonide on symptoms, quality of life, and performance in elite athletes with allergic rhinoconjunctivitis. Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine. 2002;12(5):296-300.
82. Hox V, Lourijsen E, Jordens A, Aasbjerg K, Agache I, Alobid I, et al. Benefits and harm of systemic steroids for short- and long-term use in rhinitis and rhinosinusitis: an EAACI position paper. Clinical and translational allergy. 2020;10:1.
83. Simons FE. Advances in H1-antihistamines. The New England journal of medicine. 2004;351(21):2203-17.
84. Banov CH, Lieberman P, Vasomotor Rhinitis Study G. Efficacy of azelastine nasal spray in the treatment of vasomotor (perennial nonallergic) rhinitis. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology. 2001;86(1):28-35.
85. Gehanno P, Deschamps E, Garay E, Baehre M, Garay RP. Vasomotor rhinitis: clinical efficacy of azelastine nasal spray in comparison with placebo. ORL J Otorhinolaryngol Relat Spec. 2001;63(2):76-81.
86. Price D, Shah S, Bhatia S, Bachert C, Berger W, Bousquet J, et al. A new therapy (MP29-02) is effective for the long-term treatment of chronic rhinitis. Journal of investigational allergology & clinical immunology. 2013;23(7):495-503.
87. Kortekaas Krohn I, Callebaut I, Alpizar YA, Steelant B, Van Gerven L, Skov PS, et al. MP29-02 reduces nasal hyperreactivity and nasal mediators in patients with house dust mite-allergic rhinitis. Allergy. 2018;73(5):1084-93.
88. Farre M, Perez-Mana C, Papaseit E, Menoyo E, Perez M, Martin S, et al. Bilastine vs. hydroxyzine: occupation of brain histamine H1 -receptors evaluated by positron emission tomography in healthy volunteers. British journal of clinical pharmacology. 2014;78(5):970-80.
89. Passalacqua G, Bousquet J, Bachert C, Church MK, Bindsley-Jensen C, Nagy L, et al. The clinical safety of H1-receptor antagonists. An EAACI position paper. Allergy. 1996;51(10):666-75.

90. Philip G, Nayak AS, Berger WE, Leynadier F, Vrijens F, Dass SB, et al. The effect of montelukast on rhinitis symptoms in patients with asthma and seasonal allergic rhinitis. Current medical research and opinion. 2004;20(10):1549-58.
91. Roberts G, Pfaar O, Akdis CA, Ansotegui IJ, Durham SR, Gerth van Wijk R, et al. EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis. Allergy. 2018;73(4):765-98.
92. Lekakis G, Dekimpe E, Steelant B, Hellings PW. Managing nasal valve compromise patients with nasal dilators: objective vs. subjective parameters. Rhinology. 2016;54(4):348-54.
93. Dinardi RR, de Andrade CR, Ibiapina Cda C. External nasal dilators: definition, background, and current uses. International journal of general medicine. 2014;7:491-504.
94. Gelardi M, Porro G, Accettura D, Quaranta VN, Quaranta N, Ciprandi G. The role of an internal nasal dilator in athletes. Acta bio-medica : Atenei Parmensis. 2019;90(2-s).
95. Tong TK, Fu FH, Chow BC. Nostril dilatation increases capacity to sustain moderate exercise under nasal breathing condition. The Journal of sports medicine and physical fitness. 2001;41(4):470-8.
96. Ottaviano G, Ermolao A, Nardello E, Muci F, Favero V, Zaccaria M, et al. Breathing parameters associated to two different external nasal dilator strips in endurance athletes. Auris, nasus, larynx. 2017;44(6):713-8.
97. Dinardi RR, de Andrade CR, Ibiapina Cda C. Evaluation of the effectiveness of the external nasal dilator strip in adolescent athletes: a randomized trial. International journal of pediatric otorhinolaryngology. 2013;77(9):1500-5.
98. van Egmond M, Rovers MM, Tillema AHJ, van Neerbeek N. Septoplasty for nasal obstruction due to a deviated nasal septum in adults: a systematic review. Rhinology. 2018;56(3):195-208.
99. Lennon P, Jaber S, Fenton JE. Functional and psychological impact of nasal bone fractures sustained during sports activities: A survey of 87 patients. Ear, nose, & throat journal. 2016;95(8):324-32.
100. Hellings PW, Fokkens WJ, Bachert C, Akdis CA, Bieber T, Agache I, et al. Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis - A EUFOREA-ARIA-EPOS-AIRWAYS ICP statement. Allergy. 2017;72(9):1297-305.
101. Global drug reference online [Available from: https://www.globaldro.com/Home.
102. Hens G, Hellings PW. The nose: gatekeeper and trigger of bronchial disease. Rhinology. 2006;44(3):179-87.
103. Stickland MK, Rowe BH, Spooner CH, Vandermeer B, Dryden DM. Effect of warm-up exercise on exercise-induced bronchoconstriction. Medicine and science in sports and exercise. 2012;44(3):383-91.

104. Seys SF, Bousquet J, Bachert C, Fokkens WJ, Agache I, Bernal-Sprekelsen M, et al. mySinusitisCoach: patient empowerment in chronic rhinosinusitis using mobile technology. Rhinology. 2018;56(3):209-15.
105. Bonini M, Bachert C, Baena-Cagnani CE, Bedbrook A, Brozek JL, Canonica GW, et al. What we should learn from the London Olympics. Curr Opin Allergy Clin Immunol. 2013;13(1):1-3.
106. Bonini S, Bonini M, Bousquet J, Brusasco V, Canonica GW, Carlsen KH, et al. Rhinitis and asthma in athletes: an ARIA document in collaboration with GA2LEN. Allergy. 2006;61(6):681-92.

Tables

Table 1

Treatment/intervention	Disease	WADA rules	Notes
Trigger avoidance	AR, NAR, CRS	Allowed	Not always feasible to achieve.
Saline douchings	AR, NAR, ARS, CRS	Allowed	Very safe and cheap treatment option recommended as an adjunct for all mucosal pathology. Might be considered specifically for symptomatic swimmers after leaving a chlorinated pool.
Decongestants	Infectious rhinitis, ARS	Allowed: phenylephrine, phenylpropanolamine, adrenaline, xylometazoline and synephrine Allowed in limited concentrations: cathine, ephedrine and methylephedrine, pseudoephedrine Not allowed: sympathomimetic amines	Overuse can lead to rhinitis medicamentosa with paradoxal chronic nasal obstruction.
Intranasal corticosteroids	AR, NAR, ARS, CRS	Allowed, TUE is not required	Transient side effects: minor epistaxis, nasal dryness and irritation of nose and throat. Golden standard for chronic mucosal sinonasal pathology.
Oral corticosteroids	Severe therapy-resistant AR	Allowed with TUE. Indications are rare for AR.	Gastro-intestinal, cardiovascular, ocular, psychiatric side-effects. Avascular necrosis, suppression of HPA-axis,

			osteopenia, diabetes mellitus, increased infection rate.
Antihistamines	AR	Allowed	Side effect: first-generation antihistamines can have a sedative effect. Second-generation and later antihistamines are less sedative.
Cromoglycates	AR	Allowed	Less effective in suppressing nasal symptoms than antihistamines.
Antileukotrienes	AR	Allowed	Comparable efficacy to antihistamines, but no sedation.
Allergen Immunotherapy	AR	SLIT: Allowed SCIT: Allowed	Immunotherapy should be started before competition. Local and systemic side effects are reported, more in SCIT than in SLIT. Exercise is prohibited on day of injection for SCIT.
Nasal dilators	Structural pathology	Allowed	No clear effect on physiological parameters, however, beneficial effect on subjective breathing.
Surgery	Structural pathology, AR, NAR, CRS	Permitted	(Rhino)septoplasty is an option for medically resistant nasal obstruction in the presence of structural abnormalities. Turbinoplasty can be considered in medically resistant, reversible nasal obstruction due to turbinate hypertrophy. Endoscopic sinus surgery is an

			option in CRS patients in whom maximal medical therapy has failed.

Table 1: Treatment options for nasal symptoms in athletes according to the causal pathology and the current WADA regulations [72]. AR: allergic rhinitis; NAR: non-allergic rhinitis; ARS: acute rhinosinusitis; CRS: chronic rhinosinusitis; SCIT: subcutaneous immunotherapy; SLIT: sublingual immunotherapy; TUE: therapeutic use exemption; HPA: hypothalamic-pituitary-adrenal

Table 2

P	Problem	Proposed solution
Prediction	- Certain sport-specific factors are believed to predispose to upper airway symptoms.	- Screen athletic populations at risk (e.g. aquatic sports, ultra-endurance athletes) regularly for upper airway symptoms.
	- Certain athletes will be bothered more by nasal symptoms than others	- Evaluation of the **impact on QOL** of the nasal symptoms by QOL-specific questionnaires: • NOSE (nasal obstruction) • RQLQ (rhinitis) • SNOT-22 (rhinosinusitis) → moving up treatment scheme more rapidly in patients with severe impact.
	- Outdoor athletes suffering from seasonal allergies will suffer more during pollen seasons.	- **Perform allergy testing**(AQUA + SPT/serum test) **in symptomatic athletes** in order to predict and manage the symptomatic period depending on a specific country's pollen season.
	- Rhinitis and rhinosinusitis are risk factors in the development of asthma or BHR	- Screen athletes with rhinitis and rhinosinusitis for lower airway problems.
Prevention	- Environmental airway irritants can trigger and/or cause nasal symptoms.	- **Avoid irritants where possible**: • Aquatic athletes: - non-chlorinated pools if available. - Monitor and adapt environmental levels of

		chlorination (by)products. • Outdoor athletes should avoid training in (highly) polluted environments.
	- Outdoor athletes suffering from seasonal allergies will suffer more during pollen seasons. - Exposure to cold-dry air induces NHR - Increased ventilation might induce dehydration of the nasal mucosa.	- **Athletes with seasonal allergies should be treated accordingly** (AH, AIT) when performing outdoor during the allergy season**or train indoor**. - Pre-exercise warm-up respiratory exercises? (to be investigated). - Pre-exercise saline nasal douching? (to be investigated)
Personalization	- Different types of nasal symptoms require different management options	- **Individual diagnosis and adaptation of therapeutic option accordingly:** • structural vs. inflammatory pathology • allergic vs. non-allergic cause of inflammation • rhinitis vs. rhinosinusitis **Follow diagnostic algorithm**
Participation	- adherence to prescription drugs has been shown difficult in athletes	- **information and education of athletes** and physicians about • their disease and its impact • action of prescribed drugs • known side-effects of drugs • prohibition status by WADA can increase adherence. Smartphone applications might play

		a role.

Table 2. Application of the 4P's-concept of personalized medicine for the management of nasal symptoms within the athletic population. Priorities are highlighted in bold.BHR: bronchial hyperreactivity; QOL: quality of life; NOSE: nasal obstruction symptom evaluation); RQLQ: rhinoconjunctivitis quality of life questionnaire; SNOT: sino-nasal outcome test; NHR: nasal hyperreactivity; AH: antihistamine; AIT: allergen immunotherapy; WADA: world anti-doping agency

Table 3.

Open research questions	Futurestudyperspectives
Accurate epidemiological knowledge on different types of upper airway pathology	- Design proper epidemiological studies in large and variable populations of athletes, including correct definitions of AR, NAR and CRS, preferably with doctor visits for proper diagnosis.
The direct impact of nasal symptoms on athletic performances	- More studies investigating sport-specific performances in athletes with nasal symptoms due to AR (in and out of season) or structural pathology (before and after surgery).
Knowledge on the concept of EIR	- Study whether post-endurance rhinitis is due to either infectious, environmental or endogenous triggers. - Properly designed mechanistic studies on the effect of strenuous exercise on the nasal airway physiology / immunology. - Properly designed mechanistic studies on the effect of different sport-related environmental factors on the nasal airway physiology / immunology.
Diagnosis and management of EIR	- Studies to evaluate symptoms and nasal patency in patients before and after exercise. - Development of a test to diagnose EIR - Investigating the effects of pre-exercise warm-up exercises or nasal humidification on nasal symptoms
The role and management of nasal structural pathologies in athletes	- Mapping the presence of structural pathologies within the athletic population and their effects on subjective nasal breathing and sports performances - Studying the objective and subjective effects of nasal dilators in athletes with nasal valve dysfunction.

Table 3. Open Research questions and unmet needs in the field of nasal disease in athletes are mentioned in the left column. In the right column proposals are given for studies that can answer these questions. AR: allergic rhinitis; NAR: non-allergic rhinitis; CRS: chronic rhinosinusitis. EIR: exercise-induced rhinitis.

Figure Legends

Figure 1: Immunological mechanisms contributing to upper airway symptoms in athletes.

Different sport-specific exogeneous triggers to which athletes are exposed (cold, pollution, environmental irritants, increased ventilatory flow) are believed to trigger the respiratory sinonasal epithelium, as well as the underlying nervous system. This activation can lead to the direct induction of nasal symptoms such as rhinorrhea, itch and NHR. Long-term or repetitive exposure to these triggers might lead to an activation of the innate and adaptive immune system, inducing a more chronic nasal inflammation. Th2: T helper 2 lymphocyte; IL: interleukin; TRP: transient receptor pontential; CGRP: calcitonin gene related peptide.Created with BioRender.com.

Figure 2. Implementation of personalized medicine to the management of an athlete with nasal symptoms. SNOT-22: sino-nasal outcome test-22 questionnaire; RQLQ: rhinoconjunctivitis quality of life questionnaire; NOSE:nasal obstruction symptom evaluation. Created with BioRender.com.

Figure 3. Diagnostic flow chart of a hypothetical athlete presenting with nasal symptoms.

The flow chart is based on initial type and timing of symptom presentation. By combining elements from history with clinical examination, rhinoscopy, nasal endoscopy, imaging, nasal patency measurements and technical examinations, an adequate differential diagnosis can be made in an athlete with nasal symptoms. When a diagnosis has been made, the impact on QOL (determined by means of specific questionnaires) and sports performance will determine the velocity by which more advanced therapeutic strategies will be initiated. AQUA: allergy questionnaire for athletes; SPT: skin prick test; QOL: quality of life; SNOT-22: sino-nasal outcome test-22 questionnaire; RQLQ: rhinoconjunctivitis quality of life questionnaire; NOSE:nasal obstruction symptom evaluation questionnaire; NHR: nasal hyperreactivity.



all_14786_f1.png



all_14786_f2.png